

CUMULATIVE INDEX 1992

Volume 10

March	EPIDURAL AND SPINAL ANALGESIA AND ANESTHESIA: CONTEMPORARY ISSUES, pages 1-210
June	CURRENT CONCEPTS IN ACUTE PAIN CONTROL, pages 211-451
September	CEREBRAL PROTECTION, RESUSCITATION, AND MONITORING: A LOOK INTO THE FUTURE OF NEUROANESTHESIA, pages 453-753
December	EMBOLISM I, pages 755-927

Note: Page numbers of issue and article titles are in **boldface** type

Acetaminophen, for pediatric analgesia, 367

Acidosis, intracellular, 457

Acoustic neuroma, monitoring with sensory-evoked potentials (SEPs), 670-671

Acute pain control. See *Pain control, acute*.

Adenosine triphosphate, pain sensitization caused by, 251

Adjuvants in epidural and spinal anesthesia, 13-30

α_2 -adrenergic agents, 24-25

alterations of physicochemical properties, carbonation and alkalinization, 14-16

dextrose and water, 16-17

pharmacologic enhancement of anesthetic effect, 17-26

warming of local anesthetics, 16

definition of, 113

epinephrine and other sympathomimetics, 17-24

contraindications, 24

in epidural analgesia for labor, 70-71

history of use, 17-18

intensity of analgesia and anesthesia, 19-20

optimal dose, 21-22

prolongation of duration of neural blockade, 18-19

reduction and delay of systemic absorption, 19

reduction of tachyphylaxis by, 21

spinal cord blood flow and, 23-24

systemic effects when injected into epidural space, 22

used as a test dose, 20-21

uterine effects, 23

opioids, in epidural analgesia for labor, 71-72

in epidural and spinal anesthesia, 25-26

Adult respiratory distress syndrome (ARDS), 761, 762

Afferent pathways, 221-223

Age, and electroencephalographic monitoring, 700

and outcome of cardiopulmonary resuscitation, 627-628

Agonist-antagonist narcotics, 383. See also α_2 -Agonists.

Air, as alternative test dose, 54

identifying loss of resistance, 74

Air embolism, 478-483

adverse effects, 479-480

caused by positive end expiratory pressure (PEEP), 812-813

monitoring, 480-481

positive end-expiratory pressure (PEEP), 482-483

sitting position in posterior fossa surgery, 478-483

treatment, 481-482

Airway management, after head injury, 611-613
in spinal cord surgery, 502-503, 503-504

Alfentanil, for epidural postoperative analgesia, 328

Alkalization of local anesthetics, 14-15

α_2 -Adrenergic agents, as an adjuvant to epidural and spinal anesthesia, 24-25

α_2 -Agonists, 312-315
clonidine, 313-315, 330-332, 406
dexmedetomidine, 315
for epidural postoperative analgesia, 330-332
for preventing urinary retention, 423

Ambulation, for preventing deep vein thromboembolism, 836

Amino acids, excitatory, and central sensitization, 259

21-Aminosteroids, 594

AMPA receptor, 585, 588

Analgesic agents, systemic. See *Systemic analgesic agents*.

Analog Chromatic Continuous Scale, 360

Aneurysms. See also *Subarachnoid hemorrhage therapy*.
atrial septal aneurysm, 802, 805, 813-814
cerebral aneurysm clipping, 671-672
incidence, 521-522
in posterior fossa, 474-475

Anti-inflammatory agents, in critically ill patients, 398
nonsteroidal, for pediatric analgesia, 367-368
prevention of secondary hyperalgesia, 214

Anticoagulation therapy, and antiplatelet therapy, 1-11. See also *Platelet aggregation inhibitors*.
antiplatelet therapy, 6-7
central neuraxial blockade and anticoagulants, 4-6
clotting mechanism, 3
complications, 1-2, 5-6
direct anticoagulants, 3-4
indirect anticoagulants, 2-3
pharmacologic parameters, 9
recommendations, 7-9
thrombolytic therapy, 6
for cerebral protection, 462
for thromboembolism. See also *Thrombolytic therapy*.
algorithms for patient management, 845-846
coumarin, 834-835, 849
dextran, 835-836
dihydroergotamine (DHE) and heparin, 832-833

heparin, compared with thrombolytic agents, 888, 889
for deep vein thrombosis, 830-834
dosage, 847
in general surgery, 839-843
guidelines for use, 849
in gynecologic surgery, 842-843
hemorrhage, as complication of, 843, 883, 885
low molecular weight heparins, 830-832, 885
in neurosurgery, 841
in orthopedic surgery, 843
with regional anesthesia, 856
in trauma patients, 846
treatment of pulmonary embolism, 881, 882-883, 885-886
in urologic surgery, 841-842

regional anesthesia and, 855-857
full anticoagulation, 856
intraoperative anticoagulation, 857
low-dose anticoagulation, 856-857
trauma patients, 845-846
warfarin, 843, 849

Antiplatelet therapy. See under *Anticoagulation therapy*.

Apnea in neonates, as postoperative complication, 141-142

Arachidonic acid, and cell destruction after ischemia, 582, 589-590
pain sensitization caused by, 251

Arachnoid cysts, 474

Arnold-Chiari malformations, hydrocephalus and, 540
preoperative neurologic assessment, 652-653
surgery, 472

Arteriovenous malformations, and pediatric neuroanesthesia, 556-559
in posterior fossa, 475

Aspartate, 259-260, 585, 586. See also *NMDA (N-methyl-D-aspartate) receptor*.

Assessment of neurologic function. See *Preoperative assessment of neurologic function*.

Astrocytomas, cerebellar, 472

ATP, cerebral consumption of, 568-569, 570-571
synthesis in the brain, 564-565

Atrial septal abnormalities, 799-801
atrial septal aneurysm, 802, 805, 813-814
locations of defects (illustration), 800
ostium primum, 801
ostium secundum, 799, 801
patent foramen ovale, 801-802
sinus venosus, 801

Atrial septum. See *Interatrial septum and systemic embolism*.

Autotomy, in animals, 257-258

B-mode ultrasonography, for diagnosis of deep vein thrombosis, 828-830
duplex scanning, 828-829

Backache, postpartum, 81

BAEPs (Brain stem auditory-evoked potentials), 661, 667, 670-671

Barbiturates, for cerebral protection, 460-461
and electroencephalographic monitoring, 707
for obstetric pain management, 384

Baricity and spinal anesthesia, 31-43
drugs and recommendations, 39-41
duration, 38-39
history, 31-33
intrathecal drug spread, 33-38
 clinical interactions and, 37
 definitions, 33-34
 dosage, 34-35
 level of injection, 36
 minor differences in baricity, 37-38
 patient characteristics, 36
 patient posture, 35
 solution baricity, 34
 volume and rate of injection, 35-36

Benzodiazepines, for cerebral protection, 465
and electroencephalographic monitoring, 708-709
for obstetric pain management, 384
for pain control in critically-ill patients, 407

β-Blockade, and test doses, 47

Blood-brain barrier, and cerebral ischemia, 457-458

Blood flow. See *Cerebral blood flow*.

Blood patch, epidural, 169-173
 complications, 172-173
 ideal volume, 171
 mechanism of action, 171
 after neonatal spinal anesthesia, 142
 prophylactic blood patch, 171-172

Blood transfusion, and risk of thromboembolic disease, 854

Brachial plexus block, 350-352, 369, 401

Bradykinin, pain sensitization caused by, 251, 253

Brain edema. See *Cerebral edema*.

Brain neoplasms, brain stem gliomas, 473
 future therapeutic methods, 723-724

Brain stem auditory-evoked potentials (BAEPs), 661, 667, 670-671

Bupivacaine, baricity, 40
 carbonation and alkalinization, 15-16, 114

combined with adjunct drugs, 70-72, 113-114, 156
combined with morphine, 329-330
continuous infusion of, 402
in epidural anesthesia during labor, 65-66, 69-70, 108-109
fetal and neonatal effects, 109-110
history, 32-33
in neonatal spinal anesthesia, 137, 140
in obstetric pain management, 387
and thromboembolic disease, 854
warming of, 16

Buprenorphine, oral administration, 272

C-fiber neuropeptides, in central sensitization, 219-220, 259-260
 in peripheral sensitization, 213-214

C-fos proto-oncogene, and central sensitization, 262-263

Caffeine, as therapy for postdural puncture headaches, 168-169

Calcitonin gene-related peptide, central sensitization and, 259-260

Calcium, in cell physiology, 579-580
and cerebral ischemia, 456
entry into cells during ischemia, 581-582

intracellular, and central sensitization, 260, 262

Calcium channel antagonists, cerebral protection and resuscitation, 461, 583-585
resuscitation of spinal cord injuries, 507
subarachnoid hemorrhage therapy, 526-527, 532

Calf vein thrombosis, 872

Capsaicin, 315-316

Carbon dioxide, and cerebral protection, 460
and electroencephalographic monitoring, 700

Carbonation and alkalinization of local anesthetics, adjuvant effect, 14-16, 70
in cesarean deliveries, 113-114

Cardiopulmonary resuscitation and cerebral outcome, 619-643
anesthesia and CPR, 630-631
anesthetic-related deaths, 631
history, 619-621
in-hospital CPR, 625, 626-627
near drowning, 630
out-of-hospital CPR, 621-625
patient selection for CPR, 634-636
pediatric and neonatal CPR, 628-629
survival improvement, 631-634
trauma and CPR, 629-630

Cardiovascular effects of systemic analgesics, clonidine, 314-315
 dezocine, 305
 ketorolac, 310

Cardiovascular performance in embolism, 755-780
 anesthesia and hypertension, 775-776
 hemodynamic management, 771-776
 pulmonary vascular bed, 769-771
 right ventricle, 757-769
 anatomy and physiology, 758-761
 impact of therapy on performance, 766-769
 performance in pulmonary embolism, 757-758, 764-766
 resuscitation, 761-764
 vascular bed, 755-757

Cardiovascular system, preoperative neurologic assessment of, 647
 response to head injury, 609-610, 648

Carotid endarterectomy, monitoring with somatosensory-evoked potentials (SSEPs), 672

Catecholamines, as adjunct to local anesthetics, 112-113
 as a test dose, 52-53
 treatment of right ventricular failure, 764

Catheters, complications in epidural analgesia for labor, blood vessel puncture, 80
 failed or unsatisfactory block, 80-81
 postpartum backache, 81
 in continuous spinal anesthesia, breaking of catheters, 94
 complication of placement, 92, 94
 placement, 88-91
 small gauge catheters, 91
 spinal headaches and, 94-95
 32-gauge catheters, 92

Cauda equina syndrome, 95, 97-101

Cavernous angiomas, in posterior fossa, 475

Cellular messengers, and central sensitization, 260-262

Central rostral-caudal deterioration, after head injury, 605-606

Central sensitization, 219-221, 254-263
 causes of, 219-220
 of dorsal horn neurons, 255-263
 alterations in flexion reflexes, 257
 animal models of persistent pain, 257-259
 cellular messengers and, 260-262
 molecular events and, 262-263
 neurochemical mediators of sensitization, 259-260
 receptive field expansion, 255-257
 prevention of, 220-221

as a result of tissue injury, 254-263

Cerebellar infarction, 473

Cerebellar tumors, 472-473

Cerebellopontine angle tumors, 473-474, 670-671

Cerebral aneurysm clipping, monitoring with sensory-evoked potentials (SEPs), 671-672

Cerebral blood flow, and brain ischemia, 455-456
 after head injury, 609
 and intracranial pressure, 645-646
 in pediatric neuroanesthesia, 538-539
 regulation, 454

Cerebral death, defined, 651

Cerebral edema, after head injury, 609
 in pediatric neuroanesthesia, 539, 543-544

Cerebral ischemia, 575-577
 blood-brain barrier, 457-458
 and calcium, 456
 calcium influx, 581-582
 cellular physiology, 577-580
 cerebral blood flow, 455-456
 electroencephalographic monitoring, 701-702, 709-711
 excitotoxic damage, 456-457
 free radicals, 457
 intracellular acidosis, 457
 membrane changes, 581
 mitochondrial dysfunction, 581
 pathophysiology, 455, 580-595
 resuscitation after prolonged ischemia, 575-577
 secondary consequences, 576
 selective vulnerability, 576-577
 vascular changes, 580-581

Cerebral protection, resuscitation, and monitoring, cardiopulmonary resuscitation and cerebral outcome, 619-643
 anesthesia and CPR, 630-631
 history, 619-621
 in-hospital CPR, 625, 626-627
 near drowning, 630
 out-of-hospital CPR, 621-625
 patient selection for CPR, 634-636
 pediatric and neonatal CPR, 628-629
 survival improvement, 631-634
 trauma and CPR, 629-630

cerebral protection and neuroanesthesia, 453-469
 anesthetics and cerebral protection, 462-465
 cerebral physiology, 454-455
 methods for cerebral protection, 458-462
 pathophysiology of cerebral injury, 455-458

electroencephalographic monitoring, 683-718
 clinical correlation, 699-703
 depth of anesthesia, 703-709
 interpretation, 690-699
 ischemia monitoring, 709-711
 measurement systems, 685-690
 physiology, 684-685
 energy metabolism and ion transport, 563-573
 cost of ion transport, 568-571
 oxidative and glycolytic ATP generation, 563-565
 regional metabolism, 565-566
 threatened energy failure, 566-568
 evoked potentials, 657-681
 classification and common modalities, 658-659
 electrophysiologic basis, 657-658
 intraoperative monitoring, 673-674
 motor-evoked potential, 659-660, 664, 667, 668, 669
 prevention of neurologic injury, 669-673
 sensory-evoked potential, 660-663, 665-669
 future of neuroanesthesia, 727-744
 cerebral protection, 733-735
 drug delivery systems, 738-739
 financial concerns, 736-737
 history of anesthesiology, 729-732
 intracranial pressure, 730-731
 monitoring, 735-737
 neuroanesthesiologists, 732-733
 stroke, 738
 future of neurosurgery, 719-726
 brain tumors, 723-724
 enhancement of neurologic function, 722
 epilepsy, 721
 ethical concerns, 719-720
 pain, 725
 trauma, 725
 vascular disease, 722-723
 head injury, 603-617
 anesthetic management, 611-614
 classification, 603-604
 neurologic assessment, 605-611
 pathophysiology, 604-605
 pediatric neuroanesthesia, 537-562
 anesthetic considerations, 541-544
 arteriovenous malformations, 556-559
 intracranial pressure, 537-540, 541
 myelodysplasia, 547-550
 pathophysiology, 540-541
 physiology, 537-540
 supratentorial procedures, 550-555
 ventricular shunts, 545-547
 posterior fossa surgery, 471-491
 air embolism, 478-483
 anatomy of posterior fossa, 471-472
 anesthesia, 483-487
 congenital malformations, 472
 intra- and extra-axial lesions, 472-474
 positioning and intraoperative considerations, 476-478
 preoperative assessment, 475-476
 vascular lesions, 474-475
 preoperative assessment of neurologic function, 645-656
 autonomic nervous system function, 648
 imaging techniques, 648-649, 651, 653
 intracranial pressure, 645-647
 respiratory and cardiovascular centers, 647-648
 specific disorders, 650-653
 resuscitation, 575-601
 cellular physiology, 577-580
 ischemia, 575-577
 pathophysiology of ischemia, 580-595
 spinal cord surgery anesthesia, 493-519
 acute spinal cord injury, 503-508
 anatomy and physiology, 493-501
 decompression of spinal cord, 501-503
 scoliosis, 508-509
 thoracoabdominal aorta surgery, 509-510
 subarachnoid hemorrhage therapy, 521-536
 anesthetic management, 529-531
 cerebral protection, 531-532
 clinical presentation, 524
 history and pathophysiology, 521-524
 preoperative diagnosis, 524-525
 surgical management, 525-529
 Cerebrospinal fluid, increased intracranial pressure after head injury, 607-608
 pediatric neuroanesthesia, 539-540
 Cerebrovascular accident, and patent foramen ovale, 810, 812
 Cervical epidural steroid therapy. See *Steroid therapy, epidural*
 Cervical plexus block, in infants and children, 368
 Cesarean delivery with neuraxial blockade, 103-127
 epidural anesthesia, 103-117
 adjuncts to local anesthetics, 112-115
 alteration of pH, 113-114
 bupivacaine, 109-110
 carbonation of local anesthetics, 113-114
 catecholamines as adjuvants, 112-113
 chloroprocaine, 110-111
 complications, 105-106
 dural puncture, 116-117

Cesarean delivery with neuraxial blockade (Continued)

- epidural venous cannulation, 105-106
- fetal and neonatal effects, 109-111
- intraoperative management, 111
- lidocaine, 110
- local anesthetic toxicity, 108-109
- maintenance of blockade, 111-112
- narcotics as adjuvants, 114-115
- nausea and vomiting, 107-108
- physiologic considerations, 106
- postoperative complications, 115-116
- preoperative management, 106-107
- technical considerations, 104-105
- spinal anesthesia, 117-121
 - advantages, 117-118
 - complications, 118-120
 - local anesthetics, 120-121
 - physiologic considerations, 118-120
 - technical considerations, 117-118
- Chest x-ray, for diagnosis of pulmonary embolism, 879-880
- Children's Hospital of Eastern Ontario Pain Scale, 360
- Chlorprocaine, in epidural anesthesia during labor, 69-70
 - fetal and neonatal effects, 110-111
 - for obstetric pain management, 387-388
- Chondrosarcomas, 474
- Chordomas, 474
- Choroid plexus neoplasms, 473
- Clivus, lesions of, 474
- Clonidine, for acute pain control, 313-315
 - as an adjuvant to epidural and spinal anesthesia, 24-25, 156, 330-332, 406
 - hemodynamic and respiratory effects, 314-315
 - pharmacokinetics, 315
- Coagulopathy, in head injury, 611
- Codeine, for pediatric analgesia, 365-366
- Coma, Glasgow Coma Scale (GCS), 603-604, 651, 652
 - preoperative neurologic assessment, 651
- Computed tomography, in preoperative neurologic assessment, 649-650
- Congestive heart failure, and pediatric neuroanesthesia, 556, 557, 558
- Continuous infusion epidural anesthesia, in labor, compared with intermittent top-ups, 74-76
 - opioids as adjuvants, 76-77
- Continuous spinal anesthesia, 87-102
 - advantages and disadvantages, 87-88
 - catheter placement, 88-91
 - cauda equina syndrome, 95, 97-101
 - complications of catheter placement, 92, 94
 - indications and contraindications, 88
- local anesthetics and intrathecal opioids, 89, 91
- small gauge catheters, 91
- spinal canal models, 97-100
- spinal headache, 94-96
- summary, 101
- 32-gauge catheter, 92-93
- Contrast two-dimensional thoracic echocardiography, 814-815
- Convulsions, caused by regional analgesia, 390
- Corticosteroids. See *Steroids*.
- Coumadin, and neuraxis blockade, 4
- Coumarin anticoagulation, interactions with other drugs, 849
 - preventing deep vein thromboembolism, 834-835
- Craniofacial procedures, neuroanesthetic considerations, 554
- Craniopharyngioma, neuroanesthetic considerations, 554-555
- Craniosynostosis, neuroanesthetic considerations, 553
- Critically ill patients, pain control in, assessing the patient's pain, 397-398
 - complications, 409-410
 - hemodynamic stability, 410-411
 - length of hospital stay, 411
 - local anesthetic techniques, 399-401
 - nonsteroidal anti-inflammatory agents, 398
- pain-related behavior, 395-396
- regional blocks, 399-401
- spinal analgesia, 401-406
 - epidural or subarachnoid blocks, 401-406
 - transcutaneous electrical nerve stimulation, 401
- summary, 411
- systemic analgesia, 407-411
 - opioids, 407-409
 - sedation, 407
- Decompression sickness, and systemic embolism, 813
- Deep vein thrombosis, 823-867. See also *Pulmonary embolism*
 - anesthesia and, 851-857
 - blood transfusion, 854
 - effects on coagulation, 853-854
 - local anesthesia, 854-855
 - lower extremity blood flow, 852
 - regional anesthesia and anticoagulant therapy, 855-857
 - regional compared with general anesthesia, 853
 - coumarin anticoagulation, 834-835, 849

dextran anticoagulation, 835-836
 diagnosis, 824-830, 876
 B-mode ultrasonography, 828-830
 combined impedance plethysmography and ¹²³I-fibrinogen scanning, 825-826
 Doppler ultrasonography, 827, 876
¹²³I-fibrinogen uptake test, 825-826, 876
 impedance plethysmography, 826-827, 876
 noninvasive procedures, 825-830, 876, 877
 venography, 825, 876
 heparin anticoagulation, 830-834, 839-843, 846, 847, 849, 856
 mechanical methods of prevention, 836-838
 prevention, 830
 risk factor assessment, 838-847
 general risk factors, 823-824, 870-871
 general surgery, 839-840
 gynecologic surgery, 842-843
 high-risk patients, 839, 871
 low-risk patients, 838-839, 870
 moderate-risk patients, 838-839, 870
 neurosurgery, 840-841
 orthopedic surgery, 843-844
 trauma patients, 844-846
 urologic surgery, 841-842
 treatment, 847-851
 inferior vena cava interruption, 848-850
 surgical treatment, 851
 warfarin anticoagulation, 847-848, 849

Descriptor Differential Scale, 239, 240

Dexmedetomidine, 315

Dextran anticoagulation, compared with low molecular weight heparins, 834
 complications, 835-836
 orthopedic surgery, 843
 preventing deep vein thromboembolism, 835-836

Dextromethorphan, 462

Dextrose, as an adjuvant in local anesthetics, 16-17

Desocine, 299-307
 abuse potential, 300-302
 adverse effects, 307
 analgesic activity, 302-303
 cardiovascular effects, 305
 clinical trials, 305-307
 increased analgesia following morphine administration, 304-305
 pharmacokinetics, 302
 respiratory effects, 303-305

Diabetes insipidus, after head injury, 614
 post-craniopharyngioma surgery, 555

Digital subtraction angiography (DISA), 816

Dihydroergotamine (DHE), combined with heparin anticoagulation, 832-833

Dobutamine, for treatment of pulmonary embolism, 768, 774, 881

Dopamine, for treatment of pulmonary embolism, 768, 881

Doppler echocardiography, of interatrial septum, 815-816

Doppler ultrasonography, for diagnosis of deep vein thrombosis, 827, 876

Dorsal horn neurons, 217-221
 central sensitization of, 219-221
 alterations in flexion reflexes, 257
 animal models of persistent pain, 257-259
 causes of, 219-220
 cellular messengers and, 260-262
 clinical significance, 220-221
 molecular events and, 262-263
 neurochemical mediators of sensitization, 259-260
 receptive field expansion, 255-257
 classes of neurons responsive to nociceptive stimuli, 217-218
 organization of, 217-218
 spinal afferent processing, 218-219
 wide dynamic range (WDR) neurons, 218-219

Drowning, and survival after CPR, 630

Dural puncture, inadvertent, 79, 116-117.
 See also *Postdural puncture headaches*.

Dyspnea, following pulmonary embolism, 783

Echocardiography, color Doppler imaging, 815-816
 contrast two-dimensional thoracic echocardiography, 814-815
 diagnosis of paradoxical embolism, 810
 interatrial septal motion, 805
 intravascular ultrasound, 816
 transesophageal echocardiography, of interatrial septum, 798, 815-816
 "straddling" thrombi across interatrial communication, 810, 811
 two-dimensional, 814

Edema. See *Cerebral edema*

Elastic stockings, for preventing deep vein thromboembolism, 836

Elderly patients, problems with test doses, 52

Electrocardiography, for diagnosis of pulmonary embolism, 879-880

Electroencephalographic monitoring, 683-718

Electroencephalographic monitoring (*Continued*)
 amplifiers, 687-688
 artifact detection, 698-699
 artifact waveforms, 692
 automated alarms and diagnosis, 699
 clinical correlation, 699-703
 depth of anesthesia, 703-709
 electrodes, 685-689
 filters, 689-690
 frequency-domain analysis, 695
 interpretation, 690-699
 ischemia monitoring, 709-711
 measurement systems, 685-690
 physiology, 684-685
 in preoperative neurologic assessment, 650-651
 quantitative analysis, 691, 693
 spectral displays, 696-698
 statistical basis of automated processing, 691
 time-domain analysis, 693-695

Electrolyte balance, and
 electroencephalographic monitoring, 700

Embolism and anesthesia, cardiovascular
 performance in embolism, 755-780
 hemodynamic management, 771-776
 pulmonary vascular bed, 769-771
 right ventricular performance, 757-769
 vascular bed, 755-757

deep vein thrombosis, 823-867
 anesthesia and, 851-857
 coumarin anticoagulation, 834-835
 dextran anticoagulation, 835-836
 diagnosis, 824-830
 heparin anticoagulation, 830-834
 mechanical methods of prevention, 836-838
 prevention, 830
 risk factor assessment, 838-847
 treatment, 847-851

interatrial septum and systemic embolism, 795-822
 atrial septal abnormalities, 799-802
 clinical implications, 816-818
 development of septum, 795-798
 imaging of interatrial communications, 814-816
 interatrial septal communications, 805-814
 normal interatrial septum, 798-799
 paradoxical embolism, 809-812
 physiology and pathophysiology, 803-809

pulmonary effects of pulmonary embolism, 781-793
 acute thromboembolization, 782-789

chronic thromboembolization, 789-791
 gas exchange, 784-789, 790-791
 lung mechanics, 782-784, 789-790

pulmonary thromboembolism, 869-904
 anesthetic effects, 894-895
 anesthetic management, 891-892
 cardiopulmonary changes after, 878-879
 chronic pulmonary thromboemboli, 895-896
 definitive treatment, 882-893
 diagnosis, 872-876
 heparin therapy, 882-883, 885-886
 inferior vena cava procedures, 892-893
 intraoperative presentation of, 893-894
 origin of emboli, 871-872
 pulmonary embolectomy, 889-891
 risk factors, 870-871
 signs and symptoms, 876-878
 supportive treatment, 880-882
 thrombolytic therapy, 886-889
 transvenous catheter embolectomy, 892

EMLA cream, 361, 363

Endocrine diseases, and
 electroencephalographic monitoring, 700-701

Energy metabolism and ion transport, 563-573
 energetic cost of ion transport, 568-571, 578
 energy changes and ionic homeostasis, 456
 hypermetabolism after head injury, 609-610
 ion homeostasis, 578-580
 oxidative and glycolytic ATP generation, 563-565
 regional metabolism, 565-566
 threatened energy failure, 566-568

Ependymal neoplasms, 473

Ephedrine, as alternative test dose, 54-55
 and thromboembolic disease, 853

Epidermoids, 474

Epidural analgesia, in critically ill patients, 402-406
 catheter placement, 402
 combined local anesthetic-opioid infusions, 406
 continuous local anesthetic, 402
 continuous opioid infusions, 406
 opioids alone, 403-406
 other agents, 406

in infants and children, 371-372
 for obstetric pain management, 385-389
 choice of local anesthetic, 387-388

contraindications, 389
management, 388-389
postoperative, 321-337
 alfentanil, 328
 α_2 -agonists, 330-332
 fentanyl, 326-327
 local anesthetics, 321-324
 meperidine, 325-326
 morphine, 324-325
 narcotic agonist-antagonists, 328-329
 opioid-local anesthetic combinations, 329-332
 opioids, 324-328
 sufentanil, 327-328
and thromboembolic disease, coagulation effects, 853-854
 effect in deep vein thromboembolism, 894-895

Epidural and spinal anesthesia, adjuvants and, 13-30
 α_2 -adrenergic agents, 24-25
 alteration of local anesthetics, 14-17
 carbonation and alkalinization, 14-16
 dextrose and water, 16-17
 epinephrine and other sympathomimetics, 17-24
 opioids, 25-26
 pharmacologic enhancement of local anesthetic effects, 17-24
 warming of local anesthetics, 16

anticoagulants and antiplatelet therapy, 1-11
 anticoagulants, 2
 antiplatelet therapy, 6-7
 central neuraxial blockade and anticoagulants, 4-6
 direct anticoagulants, 3-4
 indirect anticoagulants, 2-3
 recommendations, 7-9
 thrombolytic therapy, 6

baricity and spinal anesthesia, 31-43
 drugs and recommendations, 39-41
 duration, 38-39
 history, 31-33
 intrathecal drug spread, 33-38

cesarean delivery with neuraxial blockade, 103-127
 epidural anesthesia, 103-117
 spinal anesthesia, 117-121
 summary, 121-122

continuous spinal anesthesia, 87-102
 advantages and disadvantages, 87-88
 catheter placement, 88-91
 cauda equina syndrome, 95, 97-101
 complications of catheter placement, 92, 94

indications and contraindications, 88
local anesthetics and intrathecal opioids, 89, 91

small gauge catheters, 91
spinal headache, 94-96
summary, 101
32-gauge catheter, 92-93

intraspinal opioid analgesia, 145-162
 benefits, 146-147
 choice of opioids, 150-151
 complications, 154-155
 contraindications, 154
 drug combinations, 156-157
 economic issues, 157
 history, 145-146
 indications, 146-149
 patient-controlled analgesia, 147-149
 patient monitoring issues, 151-153
 postoperative analgesia, 149-150
 subarachnoid vs epidural administration, 147
 technical considerations, 149-155

labor and epidural analgesia, 59-85
 anatomy of epidural space, 61-63
 anesthesia for delivery, 78
 benefits, 60-61
 catheter-related complications, 80-81
 caudal block, 69
 complications, 78-79
 contraindications, 68
 epinephrine as adjuvant, 70-71
 equipment, 73
 history, 59-60
 identifying loss of resistance, 74
 indications for use, 66-68
 informed consent, 72-73
 intermittent top-ups vs continuous infusion, 74-76
 local anesthetics, 69-72
 midline or paramedian approach, 68-69
 neurologic complications, 81
 opioids as adjuvants, 71-72, 76-77
 patient-controlled analgesia, 77-78
 pH adjustment of local anesthetics, 70
 philosophy, 60
 physiologic effects, 63-65
 practical aspects, 72-78
 progress of labor, 65-66
 spinal epidural approach, 69
 techniques, 68-69
 test dose, 74

lumbar and cervical epidural steroid therapy, 179-203
 cervical epidural steroids, 187-191
 complications, 197-200
 history, 180-181
 lumbar epidural steroids, 181-187
 mechanism of action, 192-197
 opiates combined with epidural steroids, 191-192
 summary, 200-201

Epidural and spinal anesthesia (Continued)

- neonatal spinal anesthesia, 129-144
- anatomic considerations, 131-132
- apnea as postoperative complication, 141-142
- choice of drugs, 137
- history, 129-130
- indications, 130-131
- postlumbar puncture headaches, 142
- review of clinical experience, 138-141
- summary, 142-143
- technical details, 132-137
- postdural puncture headaches, 163-178
- clinical presentation, 164-165
- pathophysiology, 163-164
- prevention, 165-167
- spontaneous low cerebral spinal fluid pressure headache, 174
- summary, 174
- treatment, 167-173
- unusual managements, 173-174
- test doses, 45-58
- alternatives, 53-56
- in anesthetized patients, 52-53
- β -blockades and, 47-48
- in elderly patients, 52
- epinephrine as standard test dose, 45-46
- in pregnant patients, 48-52
- problems, 47-53
- summary, 55-56
- Epidural blood patch. See *Blood patch, epidural*.
- Epidural hematoma, 115, 855, 856
- Epidural space, anatomy of, 61-63
- Epidural test doses. See *Test doses*.
- Epilepsy surgery, future trends, 721
- pediatric neuroanesthesia, 555
- preoperative neurologic assessment, 650
- Epinephrine, effect on local anesthetics, 349
- and thromboembolic disease, 853, 881
- Epinephrine and other sympathomimetics, 17-24
- contraindications, 24
- history of use, 17-18
- intensity of analgesia and anesthesia, 19-20
- during labor, as adjuvant to local anesthetics, 70-71
- optimal concentration and dose, 21-22
- prolongation of duration of neural blockade, 18-19
- reduction and delay of systemic absorption, 19
- reduction of tachyphylaxis, 21
- spinal cord blood flow, 23-24
- systemic effects when injected into epidural space, 22
- as a test dose, 20-21
- problems in pregnant patients, 48-52
- standard test dose, 45-46
- uterine effects, 23
- Ethical concerns in neurosurgery, 719-720
- Etomidate, for cerebral protection, 465
- and electroencephalographic monitoring, 708
- Eutectic mixture of local anesthetic (EMLA) cream, 361, 363
- Evoked potentials. See *Motor-evoked potentials (MEPs); Sensory-evoked potentials (SEPs); Somatosensory-evoked potentials (SSEPs)*.
- Excitatory amino acids, ischemic damage, 456-457, 532, 585-589
- spinal cord damage, 407
- Femoral vein thrombi, 872
- Fentanyl. See also *Transdermal therapeutic system (TTS)-fentanyl*.
- for epidural postoperative analgesia, 326-327
- for obstetric pain management, 382
- for pediatric analgesia, 364-365
- and pulmonary embolism, 775
- Fetus, benefits of lumbar epidural anesthesia, 61, 67
- fatal distress caused by epinephrine, 49-50
- Flexion reflexes, alterations in, 257
- Fluid management, after head injury, 613-614
- pediatric neuroanesthesia, 543-544, 552
- posterior fossa surgery, 486-487
- volume administration, as therapy for pulmonary embolism, 767, 880
- Fourth ventricle tumors, 473
- Free fatty acids, and cell destruction, 581-582, 590
- Free radical scavengers, for cerebral protection, 462, 593-594
- resuscitation of spinal cord injuries, 507
- Free radicals, and cerebral ischemia, 457, 590-594
- production of, 591-592
- Frequency-domain analysis, of electroencephalograms, 695
- Future of neuroanesthesia. See *Neuroanesthesia, future of*.
- Future of neurosurgery. See under *Neurosurgery*.
- Gas exchange, following pulmonary embolism, in acute thromboembolization, 784-789

in chronic embolization, 790-791
 hypoxia, 784
 shunts, 784, 786, 788
 ventilation/perfusion (VA/Q) inequality, 784-789

General anesthesia, and thromboembolic disease, compared with regional anesthesia, 851-853
 lower extremity blood flow, 852
 Glasgow Coma Scale (GCS), 603-604, 651, 652

Glucose, cerebral energy metabolism requirements, 563-566
 for cerebral protection, 459, 734
 and electroencephalographic monitoring, 701
 homeostasis, in pediatric patients, 544
 resuscitation of spinal cord injuries, 506

Glutamate, and central sensitization, 259-260
 and ischemic damage, 585-589

Glycine binding, and excitatory amino acid neurotransmitters, 586, 588

GM₁ ganglioside, for resuscitation of spinal cord injuries, 508

Greenfield filter, for prevention of pulmonary emboli, 850, 893

Gynecologic surgery, and risk of deep vein thrombosis, 842-843

Halothane, and electroencephalographic monitoring, 705

Head injury, 603-617
 airway management, 611-613
 anesthetic management, 611-614
 brain edema, 609
 cardiovascular and metabolic response, 609-610
 central rostral-caudal deterioration, 605-606
 cerebral blood flow, 609
 classification, 603-604
 coagulopathy, 611
 fluid management, 613-614
 intracranial pressure, 607-608
 neurologic assessment, 605-611
 pathophysiology, 604-605
 pulmonary response, 610-611
 uncal herniation, 606-607

Headaches. See *Postdural puncture headaches*.

Hemangioblastomas, 472-473

Hematomas, cerebellar, 473
 epidural, 115, 855, 856
 intracranial, 604-605

Hemodilution, for cerebral protection, 459-460

Hemodynamic management of pulmonary embolism, 771-776

Hemodynamic result of pulmonary embolism, 770-771, 879

Hemodynamic stability, after epidural opioids, 410-411

Heparin anticoagulation, combined with dihydroergotamine (DHE), 832-833 compared with thrombolytic agents, 888, 889

in deep vein thrombosis, 830-834, 839-843, 846, 847, 849, 856

in general surgical procedures, 839-840 guidelines for therapy, 849

in gynecologic surgery, 842-843

hemorrhage, as complication of, 843, 883, 885

low-dose heparin, 830-832

low molecular weight heparins, 833-834, 885

and neuraxis blockade, 3-4, 5-6

in neurosurgery, 841

in orthopedic surgery, 843

overlapping heparin and warfarin therapy, 847

in pulmonary embolism, 881, 882-883, 885-886

regional anesthesia and, 856-857

thrombocytopenia and, 848, 885

in trauma patients, 846

urologic surgery, 841-842

Hip fractures, and deep vein thrombosis, 844-845, 846, 870

Histamine, as cause of pain sensitization, 251, 253, 254

Hydralazine, for treatment of pulmonary embolism, 768, 773-774, 882

Hydrocephalus, neonatal, 540, 547

Hyperalgesia, secondary, caused by inflammatory peptides, 214
 following tissue injury, 248
 preventing, 214

spread by central sensitization, 254-255

Hyperbaric solutions. See *Baricity and spinal anesthesia*.

Hyperoxia, for cerebral protection, 460

Hypertension, induced, for cerebral protection, 459, 734-735

Hypocapnia, following pulmonary embolism, 784, 878

Hypotension, induced, monitoring with sensory-evoked potentials (SEPs), 673
 posterior fossa surgery, 487
 spinal cord surgery, 501, 508-509

Hypotension, secondary to analgesia, 390, 402, 404

Hypothermia, causing metabolic arrest, 570

Hypothermia (*Continued*)
 for cerebral protection, 458-459, 733-734
 and electroencephalographic monitoring, 703
 monitoring with somatosensory-evoked potentials (SSEPs), 673
 in pediatric patients, 544
 resuscitation of spinal cord injuries, 506-507

Hypoxemia, following pulmonary embolism, 878

Hypoxia, cerebral metabolism and, 569-570
 and electroencephalographic monitoring, 701-702

¹²³I-fibrinogen uptake test, combined with impedance plethysmography, 826-827
 diagnosis of deep vein thrombosis, 825-826, 876

Ilioinguinalhypogastric block, 369-370

Imaging techniques, echocardiography, 814-816
 intravascular ultrasound, 816
 intravenous digital subtraction angiography, 816
 magnetic resonance imaging (MRI), 816

Impedance plethysmography, combined with ¹²³I-fibrinogen uptake test, 826-827
 diagnosis of deep vein thrombosis, 826-827, 876

Inadvertent dural puncture. See *Dural puncture, inadvertent*.

Indomethacin, for pediatric analgesia, 367

Infants and children, pain control in. See *Pediatric pain control*.

Inferior vena cava, as origin of emboli, 872
 prevention of thromboembolism, 848-850, 892-893
 Greenfield filter, 850, 893
 indications for, 850

Inflammation, 248
 and pain sensitization, 251-254

Inflammatory peptides, as cause of secondary hyperalgesia, 214

Informed consent, during labor, 72-73

Inhalational analgesia, for obstetric pain management, 381-382

Inotropic agents, dobutamine, 768, 774, 881
 dopamine, 768, 881
 effect on right ventricle, 764

following pulmonary embolism, 880-881
 isoproterenol, 53, 767, 774, 782, 880-881
 norepinephrine, 768

Intensive care patients. See *Critically ill patients, pain-control in*.

Interatrial septum and systemic embolism, 795-822
 atrial septal abnormalities, 799-802
 atrial septal aneurysm, 802
 atrial septal defect, 799-801
 patent foramen ovale, 801-802
 clinical implications, 816-818
 decompression sickness and, 813
 development of septum, 795-798
 imaging of interatrial communications, 814-816
 interatrial septal communications, 805-814
 paradoxical embolism, 809-812
 postural change and, 807
 shunting, 805-809
 motion of septum, 805
 normal interatrial septum, 798-799
 physiology and pathophysiology, 803-809
 transesophageal echocardiogram, 798

Intercostal nerve blocks, 344-346, 369, 399-400

Interpleural analgesia, in critically ill patients, 400-401
 in infants and children, 368-369
 regional block techniques, 346-350
 technique, 349-350
 in thoracotomy, 347-349

Intracranial hematomas, 604-605

Intracranial pressure, after head injury, 607-608
 imaging modalities, 647, 649-650
 improved therapy for, 729-731
 pediatric neuroanesthesia, 537-540, 541
 preoperative assessment, 645-647
 shifts of intracranial contents, 646-647

Intraspinal opioid analgesia (IOA). See *Opioids*.

Intravenous digital subtraction angiography (DISA), 816

Intravenous regional block, in infants and children, 369

Ion transport. See *Energy metabolism and ion transport*.

Iron chelation, for cerebral protection, 462

Ischemia. See *Cerebral ischemia*.

Isoflurane, for cerebral protection, 462-463
 and electroencephalographic monitoring, 705

posterior fossa surgery, 484

subarachnoid hemorrhage surgery, 531–532

Isoproterenol, as alternative test dose, 53
treatment of pulmonary embolism, 767, 774, 782, 880–881

Kainate receptors, 585

Ketamine, 384, 461, 462, 532, 708

Ketanserin, following pulmonary embolism, 882

Ketones, in cerebral metabolism, 564

Ketorolac, 307–312, 367–368
adverse effects, 309–310, 312
clinical trials, 310–312
mechanism of action, 307
for pediatric analgesia, 367–368
pharmacokinetics, 308–309
respiratory and cardiovascular effects, 310
structure, 308

Kyenuric acid, 462

Labor and epidural analgesia, 59–85
anatomy of epidural space, 61–63
benefits, 60–61
catheter-related complications, blood vessel puncture, 80
failed or unsatisfactory block, 80–81
postpartum backache, 81
complications, inadvertent dural puncture, 79
maternal hypotension, 78–79
total or high spinal block, 79
contraindications, 68
equipment and related factors, 73
history, 59–60
identifying loss of resistance, 74
indications for use, 66–68
informed consent, 72–73
intermittent top-ups vs continuous infusion, 74–76
local anesthetics, bupivacaine, 69–70
epinephrine as adjuvant, 70–71
opioids as adjuvant, 71–72
pH adjustments, 70
neurologic complications, 81
opioids added to continuous infusions, 76–77
patient-controlled analgesia, 77–78
philosophy, 60
physiologic effects, 63–65
practical aspects, 72–78
progress of labor, 65–66
techniques, caudal block, 69

midline or paramedian approach, 68–69

spinal epidural approach, 69
test dose, 48–52, 74

Language descriptive of pain. See *Measurement of pain*.

Lidocaine, for cerebral protection, 463, 465
in epidural anesthesia for labor, 69
fetal and neonatal effects, 110
in neonatal spinal anesthesia, 137
for obstetric pain management, 387
posterior fossa surgery, 484
and thromboembolic disease, 854

Lidoflazaine, for cerebral resuscitation, 583

Local anesthetics, as adjuvants, alteration of pH, 113–114
carbonation and alkalinization, 14–16
catecholamines, 112–113
during cesarean delivery, 112–115
dextrose and water, 16–17
narcotics, 114–115
warming of local anesthetics, 16
as alternative test doses, 53
in continuous spinal anesthesia, 89, 91
in critically ill patients, 399–401
effect of epinephrine, 349
for epidural analgesia, 321–324
combined with opioids, 329–332, 406
in epidural analgesia for labor, 69–72
bupivacaine, 69–70
epinephrine as adjuvant, 70–71
pH adjustment, 70
in epidural anesthesia for cesarean delivery, choice of local anesthetics, 107–108
fetal and neonatal effects, 109–111
toxicity, 108–109
hyperalgesia delayed by, 252
in infants and children, 368
pharmacologic enhancement of analgesia and anesthesia, α_2 -adrenergic agents, 24–25
by epinephrine and other sympathomimetics, 17–24
opioids, 25–26
in spinal anesthesia for cesarean delivery, 120–121
and thromboembolic disease, 854–855
for wound infiltration, 340–342, 399

Local nerve blocks. See *Regional and local blocks*.

Loss of resistance, identifying with saline or air, 74

Lumbar epidural analgesia. See *Epidural analgesia*.

Lumbar epidural steroid therapy. See *Steroid therapy, epidural*.

Lumbar plexus block, in infants and children, 370

Lung, effects of pulmonary embolism. See *Pulmonary effects of pulmonary embolism*.

Magnetic resonance imaging (MRI), of interatrial septal defects, 816 in preoperative neurologic assessment, 649-650 of pulmonary embolism, 875 Mannitol, for reducing brain edema, 543 McGill Pain Questionnaire, 232-239 administration and scoring procedures, 236-237 development and description, 232-235 discriminative capacity of, 238-239 illustration of, 235 short-form of, 239, 240, 398 spatial display of pain descriptors, 233 usefulness of, 237

Measurement of pain, 229-246

- Analog Chromatic Continuous Scale, 360
- behavioral measures, 241-242
- Children's Comprehensive Pain Questionnaire, 360
- Children's Hospital of Eastern Ontario Pain Scale, 360
- Descriptor Differential Scale, 239, 240
- dimensions of pain experience, 229-230
- language descriptive of pain, 230-231
- McGill Pain Questionnaire, 232-239
- physiologic measures, 242
- short-form McGill Pain Questionnaire, 239, 240, 398
- summary, 242-243
- Visual Analogue Scales (VAS), 231-232, 397

Mechanonociceptors, 212-213

Medulloblastomas, 472

Meningiomas, 474

Meperidine, compared with lumbar epidural anesthesia, 60-61 for epidural postoperative analgesia, 325-326 for obstetric pain management, 382

MEPs. See *Motor-evoked potentials (MEPs)*.

Methadone, for pediatric analgesia, 365

Microembolization, 781

MK-801 receptor agonist, 461-462, 507, 532

Monitoring. See also *Electroencephalographic monitoring*.

- special, for posterior fossa surgery, 485-486
- spinal cord surgery, 497-501
- venous air embolism, 480-481

Morphine, and enhancement of analgesic effects of dezocine, 304-305 for epidural postoperative analgesia, 324-325 for obstetric pain management, 382, 391-392 for pediatric analgesia, 364

Motor-evoked potentials (MEPs). See also *Sensory-evoked potentials (SEPs)*.

- anesthesia, effects on, 664, 667, 668, 669
- electrophysiologic basis, 659-660
- intraoperative monitoring, 673-674
- preoperative neurologic assessment, 653
- prevention of neurologic injury, 669-673
- spinal cord surgery, 500-501, 510
- MRI. See *Magnetic resonance imaging (MRI)*.

Muscle relaxants, and electroencephalographic monitoring, 709

Myelodysplasia, neuroanesthetic considerations, 547-550

preoperative neurologic assessment, 652-653

Naloxone, for reversing side-effects of opioids, 419, 420, 421, 424

Narcotic agonist-antagonists, for epidural postoperative analgesia, 328-329

Narcotics. See also *Opioids*.

- and electroencephalographic monitoring, 708

Nausea and vomiting, after cesarean delivery with neuraxial blockade, 107-108 after opioid anesthesia, 155, 418-420

Needles, spinal, and postdural puncture headache, 165-166

Neonatal spinal anesthesia, 129-144

- anatomic considerations, 131-132
- apnea as postoperative complication, 141-142
- choice of drugs, 137
- history, 129-130
- indications for use, 130-131
- postlumbar puncture headaches, 142
- review of clinical experience, 138-141
- summary, 142-143
- technical details, 132-137

Neuroanesthesia, future of, 727-744

- cerebral protection, 733-735
- drug delivery systems, 738-739
- financial concerns, 736-737
- history of anesthesiology, 729-732
- intracranial pressure, 730-731
- monitoring, 735-737

neuroanesthesiologists, 732-733
stroke, 738

Neuroanesthesia and cerebral protection, 453-469. See also *Cerebral protection, resuscitation, and monitoring; Pediatric neuroanesthesia*.

anesthetics and cerebral protection, 462-465

cerebral physiology, 454-455

methods for cerebral protection, 458-462

pathophysiology of cerebral injury, 455-458

suggested regimens for various clinical situations, 464

Neurologic injury, caused by regional analgesia, 390-391

Neuropeptides. See *C-fiber neuropeptides*.

Neurosurgery. See also *Posterior fossa surgery; Preoperative assessment of neurologic function*.
future of, 719-726
brain tumors, 723-724
enhancement of neurologic function, 722
epilepsy, 721
ethical concerns, 719-720
pain, 725
trauma, 725
vascular disease, 722-723
and risk of deep vein thrombosis, 840-841

Nicardipine, for cerebral resuscitation, 585

Nifedipine, and pulmonary embolism, 882

Nimodipine, for cerebral resuscitation, 583-585

Nitroprusside, and pulmonary embolism, 882

Nitrous oxide, and electroencephalographic monitoring, 705
in infants and children, 362
for posterior fossa surgery, 485
and pulmonary embolism, 775-776, 882

NMDA (*N*-methyl-*D*-aspartate) receptor, control of ion channel complex, 586-587
ischemic cell injury, 456, 532
occurrence, 585

NMDA (*N*-methyl-*D*-aspartate) receptor antagonists, 461-462, 532, 587-589

Nociception, defined, 211, 396

Nociceptors, characteristics of, 212
mechanonociceptors, 212-213
noncutaneous nociceptors, 216
peripheral receptors, 211-216
polymodal nociceptors, 213
sensitization after tissue injury, 248-250

Norepinephrine, for treatment of pulmonary embolism, 768, 771-774, 881, 882, 891

Nuclear magnetic resonance, for determination of cerebral phosphate compounds, 567

Nursing aspects of acute pain management, 435-443
developing the nursing role, 441-442
education for pain management, 427-428

primary care nurses, 433-437
role of nurse specialist, 428-429, 437-441
consultation, 438-439
education, 439-440
research, 440-441
summary, 442
team approach to pain management, 435-436

Obstetric pain management, 379-394. See also *Cesarean delivery with neuraxial blockade; Labor and epidural analgesia*.
complications of regional analgesia, 390-391
inhalational analgesia, 381-382
ketamine, 384
labor pain pathways, 380
lumbar epidural analgesia, 385-389
narcotics, 383
paracervical block, 389
psychoprophylaxis, 380
pudendal block, 390
regional analgesia, 384-391
sedatives and tranquilizers, 384
spinal narcotics, 391-392
systemic medication, 382-384
transcutaneous electrical nerve stimulation, 380-381

Opiate receptor antagonists, and resuscitation of spinal cord injuries, 506

Opioids. See also *Patient-controlled analgesia (PCA); Transdermal therapeutic system (TTS)-fentanyl*.
as adjuvants, in continuous epidural infusion, 76-77
in epidural analgesia for labor, 71-72
in epidural anesthesia for cesarean deliveries, 114-115
administration of, 271-286, 407-409
continuous intravenous infusions, 289, 407-408
oral mucosal administration, 271-273
rectal administration, 273-274
subarachnoid administration, 401-402

Opioids (Continued)

- summary, 284
- transdermal administration, 274-284
- combined with epidural steroids, 191-192
- complications of, 417-433
 - due to equipment failure, 426-427
 - hospital acute pain service for prevention of, 427-429
 - nausea and vomiting, 418-420
 - opioid-sparing strategies, 429
 - prevention of, 427-429
 - pruritus, 420-421
 - respiratory depression, 424-426
 - summary, 429-430
 - urinary retention, 422-424
- in continuous spinal anesthesia, 89, 91
- enhancement of epidural anesthesia, 25-26
- epidural, in critically-ill patients, combined local anesthetic-opioid infusions, 406
- continuous infusion, 406
- intermittent doses, 403-406
- side effects, 404-406
- for epidural postoperative analgesia, 324-328
- alfentanil, 328
- combined with local anesthetics, 329-332
- fentanyl, 326-327
- meperidine, 325-326
- morphine, 324-325
- sufentanil, 327-328
- intraspinal, in perioperative period, 145-162
 - benefits, 146-147
 - choice of opioids, 150-151
 - complications, 154-155
 - contraindications, 154
 - drug combinations, 156-157
 - economic issues, 157
 - history, 145-146
 - indications for use, 146-149
 - narcotic infusion checklist, 161-62
 - patient-controlled analgesia, 147-149
 - patient monitoring issues, 151-153
 - postoperative analgesia, 149-150
 - standard order, example, 160
 - subarachnoid vs epidural administration, 147
 - technical considerations, 149-155
- for obstetric pain management, 382
- agonist-antagonist narcotics, 382
- epidural administration, 391-392
- fentanyl, 382
- meperidine, 382
- morphine, 382
- for pediatric analgesia, 364-366
- codeine, 365-366
- fentanyl, 364-365
- methadone, 365
- morphine, 364
- sufentanil, 365
- and pulmonary embolism, 775
- Oral mucosal administration of opioids, 271-273
- Orthopedic surgery, and risk of deep vein thrombosis, 843-844
- Ostium primum (atrial septal defect), 801
- Ostium secundum (atrial septal defect), 799, 801
- Oxygen, and electroencephalographic monitoring, 701-702
- supplemental, following pulmonary embolism, 880

Pain control, acute, administration of opioids for, 271-286

- oral mucosal administration, 271-273
- rectal administration, 273-274
- summary, 284
- transdermal administration, 274-284
- complications of opioid analgesia, 417-433
- misadventure (equipment failure), 426-427
- prevention of complications, 427-429
- side effects, 418-426
- summary, 429-430
- in critically-ill patients, 395-415
 - assessing the patient's pain, 397-398
 - local anesthesia and regional blocks, 399-401
- nonsteroidal anti-inflammatory agents, 398
- pain-related behavior, 395-396
- regional blocks, 399-401
- related to complications, outcome, and length of stay, 409-411
- spinal anesthesia, 401-406
- systemic analgesia, 407-411
- in infants and children, 359-378
 - acute pain in sickle cell disease, 372
 - nonopioid analgesics, 367
 - nonsteroidal anti-inflammatory drugs, 367-368
- opioid analgesics, 364-366
- pain assessment, 359-360
- pain associated with procedures, 361-363
- patient-controlled analgesia, 366-367
- perioperative acute pain, 363-364
- regional blockade, 368-372
- summary, 372
- treatment, 361-372

measurement of pain, 229-246
 behavioral measures, 241-242
 Descriptor Differential Scale, 239, 240
 dimensions of pain experience, 229-230
 language descriptive of pain, 230-231
 McGill Pain Questionnaire, 232-239
 physiologic measures, 242
 short-form McGill Pain Questionnaire, 239, 240
 summary, 242-243
 Visual Analogue Scales (VAS), 231-232

new systemic analgesic agents, 299-320
 α_2 -agonists, 312-315
 capsaicin, 315-316
 clonidine, 313-315
 dexmedetomidine, 315
 dezocine, 299-307
 ketorolac, 307-312
 summary, 315-316

nursing aspects, 435-443
 clinical nurse specialist and, 437-441
 development of the nursing role, 441-442
 primary nurse's role, 436-437
 summary, 442
 team approach to pain management, 435-436

obstetric pain management, 379-394
 inhalational analgesia, 381-382
 labor pain pathways, 380
 psychoprophylaxis, 380
 regional analgesia, 384-391
 spinal narcotics, 391-392
 systemic medication, 382-384
 transcutaneous electrical nerve stimulation, 380-381

pain reception and processing, 211-228
 afferent pathways, 221-223
 dorsal horn and afferent processing, 217-221
 origins of pain, 211
 peripheral receptors, 211-216
 summary, 223-224

patient-controlled analgesia, 287-298
 historical perspective, 287-288
 intravenous patient-controlled analgesia, 291-296
 summary, 296
 traditional analgesic regimes, 288-291

physiologic consequences of tissue injury, 247-269
 alterations in flexion reflexes, 257
 animal models of persistent pain, 257-259
 central effects, 254-263
 central sensitization, 259-263
 neurogenic inflammation, 251-254

nociceptor sensitization, 248-250
 pain-producing substances, 250-251
 peripheral effects, 248-254
 receptive field expansion, 255-257
 sensitization of dorsal horn neurons, 255-263
 summary, 263

postoperative epidural analgesia, 321-337
 alfentanil, 328
 α_2 -agonists, 330-332
 fentanyl, 326-327
 local anesthetics, 321-324
 meperidine, 325-326
 morphine, 324-325
 narcotic agonist-antagonists, 328-329
 opioid-local anesthetic combinations, 329-332
 opioids, 324-328
 sufentanil, 327-328
 summary, 322

regional and local blocks, 339-357
 brachial plexus block, 350-352
 future developments, 352
 intercostal nerve blocks, 344-346
 interpleural analgesia, 346-350
 local anesthetic wound infiltration, 340-342
 peripheral nerve blocks, 342-344
 summary, 352

Paracervical block, 389

Paradoxical embolism, 809-812

Paravertebral block, 400

Patent foramen ovale (PFO),
 cerebrovascular accidents and, 810, 812
 and decompression sickness, 813
 defined, 798

diagnosis, with color Doppler echocardiography, 816
 with transesophageal echocardiography, 802, 816
 incidence, 801-802, 812
 and paradoxical embolism, 809-810

Patient-controlled analgesia (PCA), 287-298
 adverse reactions and side effects, 295
 in critically ill patients, 408-409
 definition of PCA modes and dosing, 291
 educational and attitudinal problems, 290-291
 historical perspective, 287-288
 individual analgesic requirements, 291-294
 in infants and children, 366-367
 intraspinal opioids vs patient-controlled analgesia, 147-149

Patient-controlled analgesia (PCA) (Continued)

- intravenous patient-controlled analgesia, 291-296
- during labor, 77-78
- machine-user interface, 295-296
- minimal effective analgesic concentration (MEAC), 288-289
- in obstetric pain management, 389
- PCA paradigm, 288-290
- pharmacodynamic factors, 292-293
- pharmacokinetic factors, 292
- psychologic factors, 293-294
- safety and problems, 294-296, 409, 426-427
- summary, 296
- traditional analgesic regimes, 288-291

PCA. See *Patient-controlled analgesia (PCA)*.

PDPH. See *Postdural puncture headaches*.

Pediatric cardiopulmonary resuscitation, 628-629

Pediatric neuroanesthesia, 537-562

- anesthetic considerations, 541-544
- arteriovenous malformations, 556-559
- brain mass reduction, 539
- cerebral blood volume, 538-539
- cerebrospinal fluid, 539-540
- craniofacial procedures, 554
- craniopharyngioma, 554-555
- craniosynostosis, 553
- intracranial pressure, 537-540, 541
- myelodysplasia, 547-550
- pathophysiology, 540-541
- physiology, 537-540
- seizure surgery, 555
- supratentorial procedures, 550-555
- ventricular shunts, 545-547

Pediatric pain control, 359-378

- acute pain in sickle cell disease, 372
- nonopiod analgesics, 367
- nonsteroidal anti-inflammatory drugs, 367-368
- opioid analgesics, 364-366
- oral administration or opioids, 272
- pain assessment, 359-360
- pain associated with procedures, 361-363
- patient-controlled analgesia, 366-367
- perioperative acute pain, 363-364
- regional blockade, 368-372
- summary, 372
- treatment, 361-372

PEEP. See *Positive end-expiratory pressure (PEEP)*

Penile block, in infants and children, 370

Peripheral nerve blocks, 342-344

- miscellaneous blocks, 344
- sciatic and femoral blocks, 343-344

Peripheral receptors, 211-213

- opioid and α_2 -receptors, 214, 216

peripheral sensitization, 213-216

Peripheral sensitization, 213-216, 248-254

- neurogenic inflammation, 251-254
- nociceptor sensitization, 248-250
- pain-producing substances, 250-251

Persistent pain, animal models of, 257-259

PFO. See *Patent foramen ovale (PFO)*.

pH of local anesthetics, changing. See *Carbonation and alkalization of local anesthetics*.

Phantom limb pain, 257-259, 258

Phencyclidine receptor agonist, 461-462, 532

Phenothiazines, for obstetric pain management, 384

Phenoxybenzamine, 423

Phlegmasia alba dolens, 851

Phlegmasia cerulea dolens, 851

Physical examination. See *Preoperative assessment of neurologic function*.

Physiologic consequences of tissue injury, 247-269

- alterations in flexion reflexes, 257
- animal models of persistent pain, 257-259
- central effects, 254-263
- central sensitization, 259-263
- neurogenic inflammation, 251-254
- nociceptor sensitization, 248-250
- pain-producing substances, 250-251
- peripheral effects, 248-254
- receptive field expansion, 255-257
- sensitization of dorsal horn neurons, 255-263
- summary, 263

Plasminogen activators, released by

- pneumatic leg compression, 837, 838

Platelet aggregation inhibitors, 854-855

Pneumatic leg compression, for

- preventing deep vein thromboembolism, 836-838
- failure in cancer patients, 838
- general surgery, 840
- gynecologic surgery, 842-843
- neurosurgery, 840, 841
- orthopedic surgery, 843-844
- release of plasminogen activators, 837
- trauma patients, 846
- urologic surgery, 842

Positions, surgical, park bench and lateral positions, 476-477

- posterior fossa surgery, 476-478
- prone, 478
- sitting position, 477-478, 478-479, 673
- spinal cord surgery, 502

Positive end-expiratory pressure (PEEP),

- air embolism and, 482-483, 812-813
- effect on atrial dynamics, 808

as supportive treatment following pulmonary embolism, 880

Positron emission tomography, in preoperative neurologic assessment, 651

Postdural puncture headaches, 163–178
caused by large-gauge needles, 94–95
clinical presentation, 164–165
common complication of epidural anesthesia, 116–117
differential diagnosis, 165
in infants and children, 95, 96, 142
pathophysiology, 163–164
prevention, 165–167
ambulation after dural puncture, 167
small spinal needle diameter, 165
spinal needle bevel orientation, 166
spinal needle tip design, 166

after regional anesthesia for obstetric pain management, 391

spontaneous low cerebral spinal fluid pressure headache, 174

summary, 174

treatment, 167–173
 caffeine therapy, 168–169
 epidural blood patch, 169–173
 epidural saline, 167–168
 unusual managements, 173–174

Posterior fossa surgery, 471–491
air embolism, 478–483
anatomy of posterior fossa, 471–472
anesthesia, 483–487
congenital malformations, 472
intra- and extra-axial lesions, 472–474
monitoring with sensory-evoked potentials (SEPs), 671
positioning and intraoperative considerations, 476–478
preoperative assessment, 475–476
vascular lesions, 474–475

Postoperative epidural analgesia. See under *Epidural analgesia*.

Potassium, as cause of pain sensitization, 251, 253

Pregnancy, urokinase thrombolytic therapy and, 889

Preoperative assessment of neurologic function, 645–656
autonomic nervous system function, 648
head-injured patients, 605–611
imaging techniques, 648–649, 651, 653
intracranial pressure, 645–647
pediatric neuroanesthesia, 542
posterior fossa surgery, 475–476
respiratory and cardiovascular centers, 647–648
specific disorders, 650–653

Propofol, and electroencephalographic monitoring, 708

Prostaglandin inhibitors, for cerebral protection, 462, 590

Prostaglandins, as cause of pain sensitization, 251, 254
cell destruction after ischemia, 589–590

Protein kinases, and central sensitization, 260, 261

Proto-oncogenes, and central sensitization, 262–263

Pruritus, after opioid anesthesia, 155, 420–421

Pudendal block, for obstetric pain management, 390

Pulmonary angiography, for diagnosis of pulmonary thromboembolism, 872–873

Pulmonary effects of pulmonary embolism, 781–793
acute thromboembolization, 782–789
chronic thromboembolization, 789–791
gas exchange, 784–789, 790–791
lung mechanics, 782–784, 789–790
pulmonary arterial hypertension, 766, 881

pulmonary edema, 783

Pulmonary embolectomy, 889–892
anesthetic management for, 891–892
mortality rates, 890
transvenous catheter embolectomy, 892
using cardiopulmonary bypass, 890, 891, 895

Pulmonary embolism, 869–904. See also *Deep vein thrombosis; Embolism and anesthesia*.
algorithms for anticoagulation therapy, 883, 884
anesthesia and, effect of anesthetic technique, 894–895
in hypertensive patients, 775–776
anesthetic management for embolectomy, 891–892
calf vein thrombosis, 872
cardiopulmonary changes after, 878–879
central vein or right heart thrombosis, 872
chest roentgenogram, ECG, and laboratory tests, 877–878
chronic pulmonary thromboemboli, 895–896
definitive treatment, 882–893
determinants of severity, 756–757
diagnosis, 872–876
Bone's schema for noninvasive diagnosis, 877
criteria for probability assessment, 873–876

Pulmonary embolism (*Continued*)
 invasive and noninvasive methods, 876
 magnetic resonance imaging (MRI), 875
 pulmonary angiography, 872-873
 ventilation/perfusion (V/Q) scans, 873-876
 hemodynamic management, 771-775
 hemodynamic result of, 770-771, 879
 heparin therapy, 882-883, 885-886
 inferior vena cava or femoral "floating" thrombi, 872
 inferior vena cava procedures, 892-893
 intraoperative presentation of, 893-894
 mortality, 869
 origins, 755, 824, 871-872
 pulmonary embolectomy, 889-891
 respiratory changes following, 878
 right ventricular performance in, 757-758, 764-769, 879
 risk factors, 756, 870-871
 signs and symptoms, 876-878
 supportive treatment, 880-882
 inotropes, 880-881
 oxygenation and ventilation, 880
 vasoactive mediators, 881-882
 volume administration, 880
 thrombolytic therapy, 886-889
 transvenous catheter embolectomy, 892
 types of emboli, 782
 Pulmonary function/complications, preventing, 409-410
 Pulmonary system. *See* Respiratory system
 Pulmonary vascular bed, in pulmonary embolism, 769-771

Quisqualate receptor, 585, 588

Rectal administration of opioids, 273-274
 Regional and local blocks, 339-357
 brachial plexus block, 350-352, 369, 401
 cervical plexus block, 368
 complications, 390-391
 in critically-ill patients, 399-401
 epidural, in infants and children, 371-372
 femoral nerve block, 370
 future developments, 352
 ilioinguinal/iliohypogastric block, 369-370
 in infants and children, 368-372
 intercostal nerve blocks, 344-346, 369, 399-400
 interpleural analgesia, 346-350, 368-369, 400-401
 intravenous regional block, 369
 local anesthetic, 340-342, 368, 399
 lumbar epidural analgesia, 385-389
 lumbar plexus block, 370
 for obstetric pain management, 384-391
 paracervical block, 389
 paravertebral block, 400-401
 penile block, 370
 peripheral nerve blocks, 342-344
 principles, 384-385
 pudendal block, 390
 sciatic nerve block, 370
 summary, 352
 Regional anesthesia, and thromboembolic disease, anticoagulant therapy and, 855-857
 beneficial effects, 851-853
 compared with general anesthesia, 853
 effect in deep vein thromboembolism, 893-895
 lower extremity blood flow, 852
 Respiratory effects of analgesia/anesthesia, clonidine, 314-315
 dezocine, 303-305
 ketorolac, 310
 opioids, 154, 404-406, 424-426
 TTS-fentanyl therapy, 278, 279, 283
 Respiratory system, impairment, due to spinal cord injury, 505
 preoperative neurologic assessment, 647-648
 pulmonary response to head injury, 610-611
 Resuscitation, 575-601. *See also* *Cardiopulmonary resuscitation and cerebral outcome*.
 cellular physiology, 577-580
 drug therapy for spinal cord injury, 505-508
 ischemia, 575-577
 pathophysiology of ischemia, 580-595
 of right ventricle, in pulmonary embolism, 761-764
 Right ventricle, in pulmonary embolism, anatomy and physiology, 758-761
 compared with left ventricle, 759
 failure due to circulatory collapse, 759-761, 879
 function and performance, 757-758, 764-766
 impact of therapy, 766-769
 resuscitation, 761-764
 Risk factors for embolism, 838-847
 common risk factors, 756
 criteria for diagnostic probability assessment, 874

deep vein thrombosis and pulmonary thromboembolism, 870-871
 general risk factors, 823-824, 870-871
 high-risk patients, 839, 871
 hypercoagulability, 870
 low-risk patients, 838-839, 870
 moderate-risk patients, 838-839, 870
 previous history of deep vein thrombosis, 823
 for surgical procedures, general surgery, 839-840, 870-871
 gynecologic surgery, 842-843
 neurosurgery, 840-841
 orthopedic surgery, 843-844
 urologic surgery, 841-842
 trauma patients, 844-846
 Virchow's risk factors, 823, 870, 871
Ropivacaine, for obstetric pain management, 387-388

Saline, for identifying loss of resistance, 74
 as therapy for postdural puncture headaches, 167-168
Schwannoma, 473-474
Sciatic nerve block, in infants and children, 370
Scoliosis, surgical correction, 508-509
Second messenger systems, and central sensitization, 260-262
Secondary hyperalgesia. See *Hyperalgesia, secondary*.
Sedation, after opioid intraspinal anesthesia, 155
Sedatives, in critically ill patients, 407 for obstetric pain management, 384
Sensitization. See *Central sensitization; Peripheral sensitization*.
Sensory-evoked potentials (SEPs). See also *Motor-evoked potentials (MEPs); Somatosensory-evoked potentials (SSEPs)*. anesthesia, effects on, 663-664, 668, 669
 classification and common modalities, 658-659
 electrophysiologic basis, 657-658
 equipment requirements for obtaining, 660
 interpretation, 661
 intraoperative monitoring of neurologic procedures, 669-673, 735
 measuring depth of anesthesia, 662-663
 preoperative neurologic assessment, 653
 prevention of neurologic injury, 669-673
 variables in intraoperative recording, 661-662
SEPs. See *Sensory-evoked potentials (SEPs)*.

Septic embolization, 782, 813
Septum. See *Interatrial septum and systemic embolism*.
Serotonin, pain sensitization caused by, 251
Shivering, after epidural anesthesia for cesarean delivery, 116
Shunting, and gas exchange, following pulmonary embolism, 784, 786, 788
 interatrial septal communications, 805-809
Sickle cell disease, acute pain in, 372
Sinus venosus (atrial septal defect), 801
Sitting position, danger of air embolism, 478-479
 monitoring with sensory-evoked potentials (SEPs), 673
 omitting nitrous oxide, 485
 posterior fossa surgery, 477-478
Skull x-rays, and preoperative neurologic assessment, 647
Somatosensory-evoked potentials (SSEPs). See also *Sensory-evoked potentials (SEPs)*.
 anesthesia, effects on, 664, 665-666
 intraoperative monitoring of neurologic procedures, 671-673
 spinal cord surgery, 498-500, 509-510
 subarachnoid hemorrhage surgery, 528-529
Spinal anesthesia. See *Epidural and spinal anesthesia*.
Spinal anesthesia, continuous. See *Continuous spinal anesthesia*.
Spinal anesthesia, total, caused by regional analgesia, 390
Spinal cord. See also *Dorsal horn neurons*. blood flow, effect of epinephrine, 23-24
 injury, and deep vein thrombosis, 845, 846
Spinal cord surgery anesthesia, 493-519 acute spinal cord injury, 503-508
 blood supply, anatomy, 493-495
 anesthesia effects, 497
 physiology, 495-497
 regulation, 496
 decompression of spinal cord, 501-503
 intraoperative monitoring, 497-501
 monitoring with sensory-evoked potentials (SEPs), 669-670
 preoperative neurologic assessment, 652
 scoliosis, 508-509
 thoracoabdominal aorta surgery, 509-510
Spinal headaches. See *Postdural puncture headaches*.
Spinal needles, and postdural puncture headache, 165-166
Spinal shock, 504-505

Spontaneous low cerebral spinal fluid pressure headache, 174

SSEPs. See *Somatosensory-evoked potentials (SSEPs)*.

Steroid therapy, epidural, 179-203
cervical epidural steroids, 187-191
complications, 197-200
history, 180-181
lumbar epidural steroids, 181-187
mechanism of action, 192-197
opiates combined with epidural steroids, 191-192
summary, 200-201

Steroids, 21-aminosteroids, 594
corticosteroids for cerebral protection, 462, 594-595
resuscitation of spinal cord injuries, 505-506

Streptokinase, compared with pulmonary embolectomy, 890
thrombolytic therapy of pulmonary embolism, 886-889
treatment of deep vein thrombosis, 848

Stroke, 738, 810, 812

Subarachnoid administration, of opioids, 401-402
of other agents, 406

Subarachnoid hemorrhage therapy, 521-536
anesthetic management, 529-531
cerebral protection, 531-532
clinical presentation, 524
history and pathophysiology, 521-524
preoperative diagnosis, 524-525
rebleeding, 523, 526, 531
risk of surgery, 524
sentinel headaches, 523, 524
surgical management, 525-529
vasospasm, 523-524, 525, 526, 584

Subarachnoid test solutions, 55-56

Substance P, and neural sensitization, 214, 253-254, 259-260

Sufentanil, for epidural postoperative analgesia, 327-328
for pediatric analgesia, 365

Supratentorial procedures, neuroanesthetic considerations, 550-555

Surgical risk factors for embolism. See *Risk factors for embolism*.

Surgical therapy of deep vein thrombosis, 851

Sympathomimetics. See *Epinephrine and other sympathomimetics*.

Systemic analgesic agents, 299-320
α₂-agonists, 312-315
capsaicin, 315-316
clonidine, 313-315
dexmedetomidine, 315

dezocine, 299-307
ketorolac, 307-312
opioids, 407-409
sedatives, 407
summary, 315-316

Systemic embolism. See *Interatrial septum and systemic embolism*.

Tachyphylaxis, reduction of, 21

Temperature, and electroencephalographic monitoring, 703
homeostasis, in pediatric patients, 544

Test doses, 45-58
alternatives, 53-56
air, 54
ephedrine, 54-55
isoproterenol, 53-54
local anesthetics, 53
subarachnoid test solutions, 55-56
epinephrine as an adjuvant, 20-21
problems, 47-53
in anesthetized patients, 52-53
β-blockade interference, 47-48
in elderly patients, 52
in pregnant patients, 48-52, 74
standard test dose, 45-46
summary, 55-56

Tetracaine, hyperbaric, in neonatal spinal anesthesia, 137-139

Third messenger systems, and central sensitization, 262-263

Thoracoabdominal aorta surgery, 509-510, 673

Thoracotomy, interpleural analgesia for, 347-349

Thrombocytopenia, as complication of heparin therapy, 848, 885

Thrombolytic therapy, 886-889
contraindications, 886
and neuraxis blockade, 6
selected regimens, 887
streptokinase, 848, 886-889, 890
tissue plasminogen activator (TPA), 769, 774-775, 886-888
urokinase, 848, 886-889

Time-domain analysis, of electroencephalograms, 693-695

Tissue injury. See *Physiologic consequences of tissue injury*.

Tissue plasminogen activator (TPA), effect on right ventricular function, 769, 774-775

thrombolytic therapy of pulmonary embolism, 886-888

Tocainide, and thromboembolic disease, 854

TPA. See *Tissue plasminogen activator (TPA)*

Tranquilizers, for obstetric pain management, 384

Transcutaneous electrical nerve stimulation, 380-381, 401

Transdermal therapeutic system (TTS)-fentanyl, 274-284

- advantages and disadvantages, 274-275
- analgesic effects, 277-282
- arterial blood gas measurements during, 280
- comparative studies, 277-279, 282
- conclusion, 282
- pharmacokinetics, 276-277
- respiratory depression, 278, 279, 283
- schematic of membrane permeation system, 275
- side effects, 278-279
- Visual Analogue Scale measurement, 280-281

Transesophageal echocardiography. See under *Echocardiography*.

Traumatic injury, and risk of deep vein thrombosis, 844-846

TTS-fentanyl system. See *Transdermal therapeutic system (TTS)-fentanyl*.

Ultrasonography, for diagnosis of deep vein thrombosis, B-mode ultrasonography, 828-830

- Doppler ultrasonography, 827

Uncal herniation, after head injury, 606-607

Urinary retention, after opioid anesthesia, 155, 422-424

Urokinase, thrombolytic therapy of pulmonary embolism, 886-889

- treatment of deep vein thrombosis, 848

Urologic surgery, and risk of deep vein thrombosis, 841-842

Uterine smooth muscle and blood flow, effect of epinephrine, 23

$\dot{V}A/\dot{Q}$ inequality. See *Ventilation/perfusion ($\dot{V}A/\dot{Q}$) inequality*.

VAS. See *Visual Analogue Scales (VAS)*.

Vascular lesions, future therapeutic methods, 722-723

- in posterior fossa, 474-475

Vasodilators, detrimental effects in pulmonary embolism, 768, 882

- for pulmonary arterial hypertension, 763

Vena cava. See *Inferior vena cava*.

Venography, for diagnosis of deep vein thrombosis, 825, 876

Venous cannulation, epidural, 105-106

Ventilation, after head injury, 611-613

- during posterior fossa surgery, 485

Ventilation/perfusion ($\dot{V}A/\dot{Q}$) scans, for diagnosis of pulmonary embolism, 873-876

Ventilation/perfusion ($\dot{V}A/\dot{Q}$) inequality, following pulmonary embolism, 784-789, 790-791

Ventricular shunts, in pediatric patients, 545-547

Visceral pain, 216

Visual Analogue Scales (VAS), assessment of TTS-fentanyl therapy, 280-281

- clinical use, 231-232
- in critically-ill patients, 397
- pediatric assessment, 359-360

Visual-evoked potentials (VEPs), 658

Volume administration, as therapy for pulmonary embolism, 767, 880

Wake-up test, in spinal cord surgery, 497-501

Warfarin anticoagulation, for deep vein thrombosis, guidelines for therapy, 849

- orthopedic surgery, 843
- overlapping heparin and warfarin therapy, 847-848

Warming, of epidural anesthetics, 116

- of local anesthetics, 16

Water, as an adjuvant in local anesthetics, 16-17

Wide dynamic range (WDR) neurons, 218-219

Wound infiltration by local anesthetics, 340-342, 399